TRMT2A

Across TCGA pan-cancer cohorts, TRMT2A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRMT2A data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRMT2A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRMT2A expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

HNSC, CCRCC, and UCEC are the cancer types where TRMT2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.524	0.864	.001	45	view →
CCRCC	DFS	Tertile	III,IV	0.461	0.849	.002	34	view →
UCEC	DFS	Tertile	All	1.000	0.904	.022	6	view →
COAD	DFS	Median	III,IV	1.000	0.835	.039	6	view →
PDAC	DFS	Quartile	II,III,IV	0.544	0.198	.020	6	view →
LUAD	OS	Median	All	0.564	0.836	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRMT2A–HNSC (DFS)

Open the HNSC breakdown →